Languages
  • Deutsch
  • Español
  • français
  • русский
  • Polski
  • العربية
  • info@iozk.de
    • Deutsch Deutsch German de
    • English English English en
    • Español Español Spanish es
    • Русский Русский Russian ru
    • polski polski Polish pl
    IOZK
    • Home
    • The IOZK
      • Philosophy
      • Team
      • Treatment Center
      • Laboratories
      • Directions and Accommodation
      • Patients Pamphlet
    • The IOZK Immunotherapy
      • IOZK Immunotherapy
      • The Vaccine IO-VAC®
      • The Treatment
      • IOZK Immunotherapy for Different Types of Cancer
      • Therapy Costs
      • FAQ
    • Expert Knowledge
      • IOZK Publications
      • Publications
      • Interesting Facts
    • News
    • Contact
    • Search
    • Menu

    The Course of Treatment

    One Immunological Concept – Individually Optimized for each Patient

    Cancer and the immune system are undergoing dynamic processes that have to be taken into account during treatment. Therefore, the IOZK-Immunotherapy is individually tailored for each patient. Thanks to its favorable tolerability, it can be performed entirely on an outpatient basis.

    The IOZK-Immunotherapy can be coordinated with other therapies such as surgery, radiation or chemotherapy, if necessary. Unlike chemotherapy or radiation, which follow a fixed timetable and pattern, IOZK-Immunotherapy is adjusted to the individual circumstances of the patient. It is continually adapted to possible modifications of the tumor and the immune system during the course of treatment.
    Cancer is a chronic disease and may, under certain circumstances, recur even after successful therapy. Therefore, it is recommended to monitor the effectiveness of the immunotherapy at certain intervals. The exact course and duration of IOZK-Immunotherapy vary greatly because they depend on the type and course of the tumor disease as well as on the individual immunological response of each patient. The first step on the way to your individual immunotherapy is the initial consultation.

    Initial Consultation

    The initial appointment at the IOZK serves to take the medical history, review all diagnostic findings, and discuss both conventional and possible immunological treatment options. This is followed by blood sampling to analyze the immune system and tumor activity, the results of which are available after about two weeks.

    PreviousNext
    12

    Development of the Therapeutic Strategy

    The team of experts meets for an internal tumor conference and discusses the results, taking into account the patient’s medical history, and develops an individual therapeutic strategy.
    This combines specially selected modules of the IOZK -Immunotherapy.

    Planning the Therapy in Cooperation with the Patient

    The recommendations of the tumor conference are then discussed with the patient. The individual therapy is planned taking into account the patient’s requirements and preferences.

    Further Information on This Topic:

    • Production of IO-VAC®
    • The Team
    • Therapeutic Hyperthermia
    • FAQ
    • What is Immunotherapy?
    • The Development of Cancer
    • Viruses Against Cancer
    • Dentritic Cells

    This post is also available in: German Spanish Russian Polish

    • FAQ
    • IOZK Immunotherapy
    • IOZK Immunotherapy for Different Types of Cancer
    • The Treatment
    • The Vaccine IO-VAC®

    The IOZK Immunotherapy

    • IOZK Immunotherapy
    • The Vaccine IO-VAC®
    • The Treatment
    • IOZK Immunotherapy for Different Types of Cancer
    • Therapy Costs
    • FAQ

    SPECIALISTS IN IMMUNO-ONCOLOGY

    NEW POSTS

    • Stefaan van Gool appointed as editor of a special issue by the Journal of Molecular Sciences
    • Award for groundbreaking discovery in immunotherapy goes to Prof. Shimon Sakaguchi
    • Symposium and Training at the IOZK: Immunotherapy in Neuro-Oncology, Friday, September 6, 2019
    • Professor Volker Schirrmacher from the IOZK opened the Symposium on Tumor Immunology at Kiel University with a talk about research on oncolytic viruses in conjunction with a personalized immunotherapy for cancer.
    • International Journal of Oncology: “From chemotherapy to biological therapy”, Prof. Dr. Volker Schirrmacher

    VIDEOS AND PATIENT REPORTS

    Keywords

    Brain Tumor Checkpoint Inhibitors Chemotherapy Dendritic Cells Dr. Wilfried Stücker Evidence Based Medicine Hyperthermia Immunotherapy IO-Vac IOZK-Symposium IOZK Foundation IOZK Immunotherapy IOZK patients pamphlet IOZK Team of Experts Liquid Biopsy Newcastle Disease Virus Nobel Prize in Medicine Oncology Oncolytic Viruses Paul Ehrlich Award Personalized Medicine Pontine Glioma Prof. Dr. rer. nat. Volker Schirrmacher Prostate Cancer Publications by Stefaan Van Gool MD. PhD. Stefaan Van Gool MD. PhD. Target Therapy Virotherapy
    IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
    Hohenstaufenring 30–32
    50674 Cologne | Germany

    T: +49 (0)221 – 420 399 25
    F: +49(0)221 - 420 399 26
    E-Mail: info@iozk.de

    The IOZK

    • Philosophy
    • Team
    • Treatment Center
    • Laboratories
    • Directions and Accommodation

    The IOZK Immunotherapy

    • IOZK Immunotherapy
    • The Vaccine IO-VAC®
    • The Treatment
    • IOZK Immunotherapy for Different Types of Cancer
    • Therapy Costs
    • FAQ

    News

    • Stefaan van Gool appointed as editor of a special issue by the Journal of Molecular Sciences
    • Award for groundbreaking discovery in immunotherapy goes to Prof. Shimon Sakaguchi
    • Symposium and Training at the IOZK: Immunotherapy in Neuro-Oncology, Friday, September 6, 2019
    © 2023 IOZK Immun-Onkologisches Zentrum Köln
    • Privacy Statement
    • Cookie Settings
    Scroll to top